Technology
Health
Pharmaceutical

Corvus Pharmaceuticals

$5.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.62 (-10.28%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell CRVS and other stocks, options, ETFs, and crypto commission-free!

About CRVS

Corvus Pharmaceuticals, Inc. Common Stock, also called Corvus Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. Read More The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Employees
49
Headquarters
Burlingame, California
Founded
2014
Market Cap
176.84M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
109.66K
High Today
$6.30
Low Today
$5.40
Open Price
$6.10
Volume
183.59K
52 Week High
$11.23
52 Week Low
$3.22

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Cancer Prevention
2016 IPO
US

CRVS Earnings

-$0.77
-$0.63
-$0.50
-$0.36
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.